Hosheng Tu,Barbara A. Niksch,David S. Haffner,Gregory T. Smedley,Olav B. Bergheim,Morteza Gharib,Richard A. Hill,Thomas W. Burns
申请号：
US15785122
公开号：
US20180161205A1
申请日:
2017.10.16
申请国别(地区):
US
年份:
2018
代理人:
摘要：
Implants and methods for treating ocular disorders are provided. One method involves introducing an implant into an anterior chamber of an eye. The implant is implanted into eye tissue adjacent the anterior chamber such that a proximal end of the implant resides in the anterior chamber following implantation. A therapeutic agent is eluted from the implant into the eye. Desirably, the release of the therapeutic agent from the implant is controlled. The controlled release of the therapeutic agent can be at a chosen rate and/or for a selected duration which can be episodic or periodic. The therapeutic agent can be an antiproliferative agent, an anti-inflammatory drug, or a compound for treating glaucoma or ocular hypertension.
